Replies to post #392113 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

re: "The U.S. government is, essentially, in control of IPIX's Brilacidin Antiviral Program"

Who are you quoting?

[CallMeCrazy]

IMO, this partially explains NIAID's interest in Brilacidin

Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic.

http://www.ipharminc.com/press-release/2020/10/30/innovation-pharmaceuticals-and-george-mason-university-announce-public-release-of-laboratory-testing-results-demonstrating-brilacidins-covid-19-treatment-potential

One existing program through which NIAID will develop safe and effective antivirals is the Antiviral Program for Pandemics (APP). The APP will focus on antivirals that directly act against viral targets, specifically for RNA viruses. Antivirals of interest will have broad use in the outpatient setting, reducing viral burden in the early stages of infection.

https://www.niaid.nih.gov/sites/default/files/pandemic-preparedness-plan.pdf

Brilacidin was tested against COVID-19 in the late stages of the disease and failed, just like the other drugs tested from Big Pharma. IMO, this left NIAID undeterred because they could see that the evidence from the COVID-19 clinical trial suggested that B could be effective as a prophylactic.

If a patient started study treatment within fewer than 7 days of onset of COVID-19 symptoms, patients in the Brilacidin 5-dose group achieved sustained recovery more quickly compared to the pooled placebo group (p=0.03). For this patient population, early treatment with Brilacidin from onset of symptoms appeared to have a potential positive impact on time to sustained recovery (the study’s primary endpoint), suggesting cases that can be treated close to initial onset of disease may be an attractive population to target for Brilacidin treatment.

http://www.ipharminc.com/press-release/2022/3/7/innovation-pharmaceuticals-reports-additional-findings-based-on-review-of-brilacidin-phase-2-covid-19-trial-results-and-compassionate-use-cases

IMO, again, NIAID was undeterred by B's failure in the late-disease-stage of COVID because they gained new data that suggest, at least in terms of COVID, that one of B-AV's roles in the therapeutic treatment process could be prophylaxis.

Much can be learned in failure.